NEW YORK--(BUSINESS WIRE)--
Market News Alerts Updates: Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO) reported fourth quarter revenue of $7.6 million, beating analyst consensus of $7.39 million. B2B2C recurring revenue surged 398% year-over-year to $5.6 million in Q4, driven by rapid employer and health plan adoption of the company's comprehensive chronic care platform. Gross margins in the B2B2C business exceeded 80% over the past three quarters.
Full-year 2024 revenue reached $27.0 million, up 32.9% from 2023, while Q4 operating loss decreased by 35% compared to Q1 2024. The company secured 36 new clients in 2024, bringing its total client base to 83 organizations with an impressive client renewal rate above 90%. Dario's solutions have demonstrated significant clinical outcomes, including a 5x ROI for payers and reducing A1C levels for diabetes patients by 2.3 points.
"Our strategic initiatives yielded remarkable financial improvements throughout 2024 in both our top and bottom line. We are already seeing this positive trajectory continue into 2025," stated CEO Erez Raphael. The company's $34.5 million cash position is expected to fund operations through to operational cash flow breakeven by the end of 2025, with an additional 20% reduction in operating expenses anticipated by Q4 2025.
Recent strategic expansions, including a Blue Cross Blue Shield agreement and integration with GLP-1 weight management programs, position Dario to continue its rapid growth trajectory in the expanding digital health market.
During the company’s earnings call, CEO Erez Raphael noted: “It's clear that 2024 was transformational year for DarioHealth. We are entering 2025 with strong momentum and solid financial foundation and a clear strategic vision that sets us apart in the healthcare technology space.”
Recent News from Dario:
* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by DarioHealth prior to publication. Please review the full disclaimers and compensation disclosures here: .
View source version on businesswire.com:
